Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 142, Issue 9, pp 2031–2040 | Cite as

Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB

  • Jizhuang Luo
  • Qingyuan Huang
  • Rui Wang
  • Baohui Han
  • Jie Zhang
  • Heng Zhao
  • Wentao Fang
  • Qingquan Luo
  • Jun Yang
  • Yunhai Yang
  • Lei Zhu
  • Tianxiang Chen
  • Xinghua Cheng
  • Yiyang Wang
  • Jiajie Zheng
  • Han Wu
  • Weicong Xia
  • Haiquan ChenEmail author
Original Article – Clinical Oncology

Abstract

Purpose

Controversy remains exist for the effect of adjuvant chemotherapy (ACT) among stage IB lung adenocarcinoma patients. This study aimed to investigate the predictive value of the current lung adenocarcinoma classification system on benefit of ACT among patients with stage IB lung adenocarcinoma.

Methods

A total of 928 pathological stage IB invasive adenocarcinoma patients with R0 resection were included in this study. Based on the predominant growth pattern present in the tumor, invasive adenocarcinomas with mixed histologic components were classified into five subtypes: lepidic (LEP), acinar (ACN), papillary (PAP), micropapillary (MIP) and solid (SOL). These five histologic subtypes were collapsed into three groups (LEP, ACN/PAP and SOL/MIP). Disease-free survival (DFS) and overall survival (OS) were analyzed to evaluate benefit from ACT in patients with different histologic patterns using the Kaplan–Meier approach and multivariable Cox models.

Results

For all stage IB invasive adenocarcinoma patients, SOL/MIP subgroup presented the worst prognosis, and LEP subgroup showed approximately 100 % 5-year survival. ACT was associated with a better DFS (HR, 0.70; 95 % CI 0.51–0.96, p = .026) for all stage IB patients. In SOL/MIP subgroup, patients could benefit from ACT for a significant improved DFS (HR, 0.81; 95 % CI 0.49–1.35; p = .030), but not for OS (HR, 0.39; 95 % CI 0.12–1.30, p = .111). In ACN/PAP subgroup, there was no significant benefit from ACT for both DFS (HR, 0.76; 95 % CI 0.54–1.08, p = .125) and OS (HR, 0.81; 95 % CI 0.49–1.35, p = .421).

Conclusions

SOL/MIP predominant pattern was predictive for ACT benefit for DFS among invasive lung adenocarcinoma patients in stage IB.

Keywords

Invasive lung adenocarcinoma Non-small-cell lung cancer Stage IB Adjuvant chemotherapy Prognosis 

Notes

Authors’ contribution

Dr Haiquan Chen is the guarantor of the manuscript. Dr Jizhuang Luo contributed to conception and study design, acquisition and analysis of data, and writing and revision of the manuscript. Dr Qingyuan Huang contributed to conception and study design, acquisition and analysis of data, and writing and revision of the manuscript. Dr Rui. Wang contributed to conception and study design, acquisition and analysis of data, and writing and revision of the manuscript. Dr Baohui Han contributed to conception and study design, acquisition and analysis of data, and revision of the manuscript. Dr Jie Zhang contributed to acquisition of data. Dr Heng Zhao contributed to acquisition of data and revision of the manuscript. Dr Wentao Fang contributed to analysis of data and revision of the manuscript. Dr Qingqian Luo contributed to analysis of data and revision of the manuscript. Dr Jun Yang contributed to acquisition of data and revision of the manuscript. Dr Yunhai Yang contributed to acquisition of data and revision of the manuscript. Dr Lei Zhu contributed to analysis of data. Dr Tianxiang Chen contributed to acquisition of data and revision of the manuscript. Dr Xinghua Cheng contributed to acquisition of data and revision of the manuscript. Dr Yiyang Wang contributed to acquisition of data and revision of the manuscript. Dr Jiajie Zheng contributed to analysis of data and revision of the manuscript. Dr Han Wu contributed to acquisition of data and revision of the manuscript. Dr Weicong Xia contributed to analysis of data and revision of the manuscript. Dr Haiquan Chen contributed to conception and study design, analysis of data and review and revision of the manuscript.

Funding

This work was funded by National Natural Science Foundation of China (81330056, 81401886, 81401891, 81422029 and 81372525) and Shen-kang Center Project (SKMB1201).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent was obtained from each patient to allow their biological samples to be genetically analyzed.

References

  1. Bueno R et al (2015) Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma. J Thorac Oncol 10:67–73. doi: 10.1097/JTO.0000000000000365 CrossRefPubMedGoogle Scholar
  2. Campos-Parra AD, Aviles A, Contreras-Reyes S, Rojas-Marin CE, Sanchez-Reyes R, Borbolla-Escoboza RJ, Arrieta O (2014) Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease. The European Respiratory Journal 43:1439–1447. doi: 10.1183/09031936.00138813 CrossRefPubMedGoogle Scholar
  3. Coutinho D, Goncalves A, Antunes A, Campainha S, Miranda J, Barroso A (2016) Adjuvant chemotherapy in stage IB non-small cell lung carcinoma: a survival analysis. Revista portuguesa de pneumologia 22:123–125. doi: 10.1016/j.rppnen.2015.09.005 CrossRefPubMedGoogle Scholar
  4. Donington JS (2016) An additional step toward personalization of surgical care for early-stage non-small-cell lung cancer. J Clin Oncol 34:295–296. doi: 10.1200/JCO.2015.64.7578 CrossRefPubMedGoogle Scholar
  5. Ettinger DS et al (2015) Non-small cell lung cancer, version 6.2015. J Natl Compr Cancer Netw JNCCN 13:515–524PubMedGoogle Scholar
  6. Friboulet L et al (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. New Engl J Med 368:1101–1110. doi: 10.1056/NEJMoa1214271 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Goldstraw P et al (2007) The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706–714. doi: 10.1097/JTO.0b013e31812f3c1a CrossRefPubMedGoogle Scholar
  8. Goldstraw P et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51. doi: 10.1016/j.jtho.2015.09.009 CrossRefPubMedGoogle Scholar
  9. Huang Q et al (2016) Identification and validation of lymphovascular invasion as a prognostic and staging factor in node-negative esophageal squamous cell carcinoma. J Thorac Oncol 11:583–592. doi: 10.1016/j.jtho.2015.12.109 CrossRefPubMedGoogle Scholar
  10. Hung JJ, Jeng WJ, Chou TY, Hsu WH, Wu KJ, Huang BS, Wu YC (2013) Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg 258:1079–1086. doi: 10.1097/SLA.0b013e31828920c0 CrossRefPubMedGoogle Scholar
  11. Li Z et al (2009) Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China. J Thorac Oncol 4:702–709. doi: 10.1097/JTO.0b013e3181a5269d CrossRefPubMedGoogle Scholar
  12. Park SY et al (2013) Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer. J Cardiothorac Surg 8:151. doi: 10.1186/1749-8090-8-151 CrossRefPubMedPubMedCentralGoogle Scholar
  13. Pignon JP et al (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552–3559. doi: 10.1200/JCO.2007.13.9030 CrossRefPubMedGoogle Scholar
  14. Pirker R (2014) Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. Transl Lung Cancer Res 3:305–310. doi: 10.3978/j.issn.2218-6751.2014.09.13 PubMedPubMedCentralGoogle Scholar
  15. Russell PA, Wright GM (2016) Predominant histologic subtype in lung adenocarcinoma predicts benefit from adjuvant chemotherapy in completely resected patients: discovery of a holy grail? Ann Transl Med 4:16. doi: 10.3978/j.issn.2305-5839.2015.10.21 PubMedPubMedCentralGoogle Scholar
  16. Shim HS et al (2015) Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol 10:1156–1162. doi: 10.1097/JTO.0000000000000579 CrossRefPubMedGoogle Scholar
  17. Takahashi Y, Eguchi T, Bains S, Adusumilli PS (2016) Significance of IASLC/ATS/ERS classification for early-stage lung adenocarcinoma patients in predicting benefit from adjuvant chemotherapy. Ann Transl Med 4:66. doi: 10.3978/j.issn.2305-5839.2015.10.40 PubMedPubMedCentralGoogle Scholar
  18. Travis WD et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285. doi: 10.1097/JTO.0b013e318206a221 CrossRefPubMedPubMedCentralGoogle Scholar
  19. Tsao MS et al (2015) Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J Clin Oncol 33:3439–3446. doi: 10.1200/JCO.2014.58.8335 CrossRefPubMedGoogle Scholar
  20. Warth A et al (2012) The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30:1438–1446. doi: 10.1200/JCO.2011.37.2185 CrossRefPubMedGoogle Scholar
  21. Wilcox JE (2006) DNA repair by ERCC1 in non-small-cell lung cancer. New Engl J Med 355:2590 (author reply 2591) CrossRefPubMedGoogle Scholar
  22. Xu CH et al (2015) Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification in stage IB lung adenocarcinoma. Eur J Surg Oncol 41:1430–1436. doi: 10.1016/j.ejso.2015.06.004 CrossRefPubMedGoogle Scholar
  23. Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G (2013) New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol 8:612–618. doi: 10.1097/JTO.0b013e318287c3eb CrossRefPubMedGoogle Scholar
  24. Yoshida T et al (2013) Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. J Cancer Res Clin Oncol 139:1691–1700. doi: 10.1007/s00432-013-1495-0 CrossRefPubMedGoogle Scholar
  25. Yoshizawa A et al (2011) Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24:653–664. doi: 10.1038/modpathol.2010.232 CrossRefPubMedGoogle Scholar
  26. Yoshizawa A et al (2013) Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 8:52–61. doi: 10.1097/JTO.0b013e3182769aa8 CrossRefPubMedGoogle Scholar
  27. Zhang J, Wu J, Tan Q, Zhu L, Gao W (2013) Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol 8:1196–1202. doi: 10.1097/JTO.0b013e31829f09a7 CrossRefPubMedGoogle Scholar
  28. Zhang Y et al (2014) The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma. Sci Rep 4:7163. doi: 10.1038/srep07163 CrossRefPubMedPubMedCentralGoogle Scholar
  29. Zhu ZH et al (2009) Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol 27:1091–1099. doi: 10.1200/JCO.2008.16.6991 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Jizhuang Luo
    • 1
  • Qingyuan Huang
    • 1
  • Rui Wang
    • 1
  • Baohui Han
    • 2
  • Jie Zhang
    • 3
  • Heng Zhao
    • 1
  • Wentao Fang
    • 1
  • Qingquan Luo
    • 4
  • Jun Yang
    • 1
  • Yunhai Yang
    • 1
  • Lei Zhu
    • 3
  • Tianxiang Chen
    • 1
  • Xinghua Cheng
    • 5
  • Yiyang Wang
    • 1
  • Jiajie Zheng
    • 1
  • Han Wu
    • 6
  • Weicong Xia
    • 6
  • Haiquan Chen
    • 1
    • 5
    • 7
    • 8
    Email author
  1. 1.Department of Thoracic Surgery, Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghaiChina
  2. 2.Department of Pulmonary Medicine, Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghaiChina
  3. 3.Department of Pathology, Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghaiChina
  4. 4.Department of Shanghai Lung Tumor Clinic Center, Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghaiChina
  5. 5.Department of Thoracic SurgeryFudan University Shanghai Cancer CenterShanghaiChina
  6. 6.Department of Thoracic Surgery, Shanghai Ruijin Hosptial, School of MedicineShanghai Jiao Tong UniversityShanghaiChina
  7. 7.Institutes of Biomedical SciencesFudan UniversityShanghaiChina
  8. 8.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina

Personalised recommendations